Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Journal article
Adler AI. et al, (2024), Lancet
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Journal article
Morrow LM. et al, (2024), J Diabetes, 16
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.
Journal article
Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal article
Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Journal article
Othonos N. et al, (2023), Nat Commun, 14
Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial.
Journal article
Oulhaj A. et al, (2023), Diabetes Obes Metab
UKPDS blood pressure study 34 year follow-up
Conference paper
Coleman RL. et al, (2023), DIABETOLOGIA, 66, S96 - S96
Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study.
Journal article
Xu S. et al, (2022), Cardiovasc Diabetol, 21
Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials.
Journal article
Preiss D. et al, (2022), Diabetes Care, 45, e1 - e2
The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized trials
Conference paper
Preiss D. et al, (2022), DIABETES RESEARCH AND CLINICAL PRACTICE, 186
Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance.
Journal article
Xu S. et al, (2021), J Diabetes, 13, 817 - 826
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Journal article
Hundertmark MJ. et al, (2021), ESC Heart Fail, 8, 2580 - 2590
Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89.
Journal article
Wamil M. et al, (2021), Diabetes Care, 44, 1877 - 1884
Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88.
Journal article
Lind M. et al, (2021), Diabetes Care
Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis.
Journal article
Juraschek SP. et al, (2021), Ann Intern Med, 174, 58 - 68
Refeeding risks in patients requiring intravenous nutrition support: Results of a two-centre, prospective, double-blind, randomised controlled trial
Journal article
Ambrose T. et al, (2021), Clinical Nutrition ESPEN
Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
Journal article
Wamil M. et al, (2020), Diabetes Res Clin Pract, 170
Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials.
Journal article
Zhou JJ. et al, (2020), Diabetologia, 63, 2482 - 2485
Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study.
Journal article
Donnelly LA. et al, (2020), Diabetes Care, 43, 2493 - 2499
Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis.
Conference paper
Juraschek SP. et al, (2020), HYPERTENSION, 76